# LENZ Therapeutics to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/LENZ/lenz-therapeutics-to-participate-in-upcoming-investor-conferences
Ticker: LENZ
Company: Lenz Therapeutics Inc
Source: Lenz Therapeutics Inc
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.lenz-tx.com
## Summary

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical…...

## Article Body
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:

William Blair 46 th Annual Growth Stock Conference Date: June 2, 2026 Location: Chicago, IL Format: 1x1 investor meetings

2026 Jefferies Global Healthcare Conference Date: June 3, 2026 Location: New York, NY Format: 1x1 investor meetings

Goldman Sachs 47 th Annual Global Healthcare Conference Date: June 9, 2026 Location: Miami, FL Format: 1x1 investor meetings

About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com .

Contacts: Dan Chevallard LENZ Therapeutics IR@LENZ-Tx.com

Source: LENZ Therapeutics, Inc. Released May 26, 2026
## Recent Company News
- 2026-07-06 12:15 EST — [LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-announces-launch-of-new-telehealth-prescribing-option-to-accel-e7f681dd) — Source: Lenz Therapeutics Inc
- 2026-06-25 13:46 EST — [LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-and-arrotex-pharmaceuticals-announce-exclusive-license-and-commercialization-agreement-for-vizztm-in-australia-and-new-zealand) — Source: Lenz Therapeutics Inc
- 2026-06-25 13:46 EST — [LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-announces-everest-medicines-acquired-rights-to-develop-and-commercialize-vizzr-lnz100-in-greater-china) — Source: Lenz Therapeutics Inc
- 2026-06-25 13:46 EST — [LENZ Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Lenz Therapeutics Inc
- 2026-06-25 13:46 EST — [LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: Lenz Therapeutics Inc
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)